Zhenshu Xu

Fujian Medical University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Rong Zhan

Fujian Medical University

Zhizhe Chen

Xi'an Jiaotong University

Peixia Tang

Institute of Hematology & Blood Diseases Hospital

Jinlan Long

Fujian Medical University

Shun‐Quan Wu

Fujian Medical University

Han Liu

Research Institute of Forestry

Mu Hao

First Affiliated Hospital of Anhui Medical University

Xiaofan Li

Fujian Medical University

Shifen Wang

Henan Normal University

Gang An

Institute of Hematology & Blood Diseases Hospital

Cooperative Institutions

Fujian Medical University

Union Hospital

Shanghai Jiao Tong University

National and Kapodistrian University of Athens

Centre for Research and Technology Hellas

Chinese Academy of Medical Sciences & Peking Union Medical College

Ruijin Hospital

Shanghai Institute of Hematology

Sun Yat-sen University

Zhejiang University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Combination of Haploidentical Hematopoietic with Low-Dose ATG, Ptcy and Cord Blood Competitive Transplantation for Hematologic Malignancies

Blood (2019)

Yi‐Ling Chen Xiaofan Li Zhenshu Xu Yuanzhong Chen Nainong Li

Cord blood

10.1182/blood-2019-127624

Cite

Citations (0)

When Patients with Plasma Cell Disorders Encountered the Largest Omicron Wave (December 2022) in China: A Real-World Multicenter and Multiregional Study

Blood (2023)

Xincheng Jiang Zhen Cai Xiaoyan Han Fengyan Jin Gang An

10.1182/blood-2023-174224

Cite

Citations (0)

Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors

Oncogene (2020)

Maolin Ge Dan Li Zhi Qiao Yan Sun Ting Kang

Abstract MLL undergoes multiple distinct chromosomal translocations to yield aggressive leukemia with dismal outcomes. Besides their well-established role in leukemogenesis, MLL fusions also possess latent tumor-suppressive activity, which can be exploited as effective cancer treatment strategies using pharmacological means such as proteasome inhibitors (PIs). Here, using MLL-rearranged xenografts and MLL leukemic cells as models, we show that wild-type MLL is indispensable for the latent tumor-suppressive activity of MLL fusions. MLL dysfunction, shown as loss of the chromatin accumulation and subsequent degradation of MLL, compromises the latent tumor suppression of MLL-AF4 and is instrumental for the acquired PI resistance. Mechanistically, MLL dysfunction is caused by chronic PI treatment-induced epigenetic reprogramming through the H2Bub-ASH2L-MLL axis and can be specifically restored by histone deacetylase (HDAC) inhibitors, which induce histone acetylation and recruits MLL on chromatin to promote cell cycle gene expression. Our findings not only demonstrate the mechanism underlying the inevitable acquisition of PI resistance in MLL leukemic cells, but also illustrate that preventing the emergence of PI-resistant cells constitutes a novel rationale for combination therapy with PIs and HDAC inhibitors in MLL leukemias.

Reprogramming

10.1038/s41388-020-01408-7

Cite

Citations (9)

Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era

Experimental Hematology and Oncology (2023)

Tingting Zhang Weiwei Tian Shuang Wei Xinyi Lu Jing An

Abstract The outbreak of coronavirus disease 2019 (COVID-19) posed an unprecedented challenge on public health systems. Despite the measures put in place to contain it, COVID-19 is likely to continue experiencing sporadic outbreaks for some time, and individuals will remain susceptible to recurrent infections. Chimeric antigen receptor (CAR)-T recipients are characterized by durable B-cell aplasia, hypogammaglobulinemia and loss of T-cell diversity, which lead to an increased proportion of severe/critical cases and a high mortality rate after COVID-19 infection. Thus, treatment decisions have become much more complex and require greater caution when considering CAR T-cell immunotherapy. Hence, we reviewed the current understanding of COVID-19 and reported clinical experience in the management of COVID-19 and CAR-T therapy. After a panel discussion, we proposed a rational procedure pertaining to CAR-T recipients with the aim of maximizing the benefit of CAR-T therapy in the post COVID-19 pandemic era.

Pandemic

2019-20 coronavirus outbreak

Coronavirus

10.1186/s40164-023-00426-x

Cite

Citations (10)

Cytogenetic abnormalities in patients with newly diagnosed multiple myeloma as a secondary primary malignancy: a retrospective study

Hematology (2020)

Yi‐Ting Wang Yong Wu Zhenshu Xu Huarong Zhou Yuanzhong Chen

Objectives: Multiple myeloma (MM) often develops as a secondary primary malignancy (SPM). The retinoblastoma susceptibility gene (RB1) was the first tumour suppressor gene to be identified. We pooled and analyzed available data to compare the incidence of RB1 gene deletions and other cytogenetic abnormalities in patients with MM alone or as an SPM.Methods: We conducted a retrospective study of 475 patients. The experimental group comprised 18 patients with MM as an SPM, and the control group comprised 457 MM patients. We analyzed the baseline information in both groups, and used the odds ratio (OR), 95% confidence interval (CI), and forest plot to determine the incidence of SPMs with and without cytogenetic abnormalities.Results: The incidence of RB1 gene deletion was higher in the experimental group. There was no significant difference in other cytogenetic abnormalities.Conclusions: RB1 gene deletions appear to be associated with MM that develops as an SPM.

10.1080/16078454.2020.1757330

Cite

Citations (5)

Younger patients with chronic lymphocytic leukemia benefit from rituximab treatment: A single center study in China

Oncology Letters (2013)

Zhenshu Xu Jinyan Zhang Shun‐Quan Wu Zhi‐Hong Zheng Zhizhe Chen

Chronic lymphocytic leukemia (CLL) is characterized by high heterogeneity in clinical features and outcomes in Western countries and China. In this study, the clinical and laboratory data of 210 CLL patients who were admitted to a single center in China between 2002 and 2011 were retrospectively analyzed. CLL patients had a median age of 60.2 years (range, 35-92 years) and CLL occurred more often in elderly female patients than in male patients (female:male, 1.2:1). The overall response rate [ORR, complete remission (CR) + partial remission (PR)] in the entire cohort of patients was 69.5% and the median overall survival (OS) was 67 months (95% CI, 57.88-76.11). In univariate analysis, an age of >60 years, chromosome 17p deletion (17p-) and elevated β2-MG were associated with a worse OS. Patients with all three poor prognostic factors had a worse outcome than patients with only one or two factors. Patients with 17p- had a significantly lower ORR (P=0.008) and shorter OS (P=0.001) than those without 17p-. Rituximab (R)-based treatment was able to overcome the poor prognosis associated with 17p-. Moreover, the addition of R to fludarabine (F) and cyclophosphamide (C) treatment significantly improved the OS (P=0.012) compared with FC alone in younger patients. However, there were no significant benefits for older patients (P=0.07). This implies that the age of a patient is important in their response to therapy and survival.

Single Center

Univariate analysis

10.3892/ol.2013.1177

Cite

Citations (10)

Arsenic trioxide and p97 inhibitor synergize against acute myeloid leukemia by targeting nascent polypeptides and activating the ZAKα–JNK pathway

Cancer Gene Therapy (2024)

Shufeng Xie Hui Liu Shouhai Zhu Zhihong Chen Ruiheng Wang

Arsenic trioxide (ATO) has exhibited remarkable efficacy in treating acute promyelocytic leukemia (APL), primarily through promoting the degradation of the PML-RARα fusion protein. However, ATO alone fails to confer any survival benefit to non-APL acute myeloid leukemia (AML) patients and exhibits limited efficacy when used in combination with other agents. Here, we explored the general toxicity mechanisms of ATO in APL and potential drugs that could be combined with ATO to exhibit synergistic lethal effects on other AML. We demonstrated that PML-RARα degradation and ROS upregulation were insufficient to cause APL cell death. Based on the protein synthesis of different AML cells and their sensitivity to ATO, we established a correlation between ATO-induced cell death and protein synthesis. Our findings indicated that ATO induced cell death by damaging nascent polypeptides and causing ribosome stalling, accompanied by the activation of the ZAKα-JNK pathway. Furthermore, ATO-induced stress activated the GCN2–ATF4 pathway, and ribosome-associated quality control cleared damaged proteins with the assistance of p97. Importantly, our data revealed that inhibiting p97 enhanced the effectiveness of ATO in killing AML cells. These explorations paved the way for identifying optimal synthetic lethal drugs to enhance ATO treatment on non-APL AML.

Arsenic Trioxide

10.1038/s41417-024-00818-z

Cite

Citations (0)

A Questionnaire Analysis of the Awareness of Blood Disease Inpatients and Their Families on Disease and Health Knowledge inside and Outside the Hospital

Blood (2023)

Yumenglin Bai Xiaolan Lian Tianyi Liang Zhenzhen Xu Zhenshu Xu

Hematology

10.1182/blood-2023-189780

Cite

Citations (0)

Mutations in the NOTCH1 PEST Domain Enhance the Expression of CCL17 By Displacing the Transcription Factor HDAC1 in Chronic Lymphocytic Leukemia